Dermapharm Holding SECHIX:DMPD 80 PEG Ratio is 2.53 as of Jun. 30, 2026, which is 86% above its 10-year median of 1.36. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €38.59. The stock has 9 warning signs investors should review. Among 346 Drug Manufacturers companies, Dermapharm Holding SE ranks worse than 61.85% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Dermapharm Holding SE's PEG Ratio or its related term are showing as below:
CHIX:DMPd'
s PEG Ratio Range Over the Past 10 Years
Min: 0.57 Med: 1.36 Max: 8.12
Current: 2.57
During the past 13 years, Dermapharm Holding SE's highest PEG Ratio was 8.12. The lowest was 0.57. And the median was 1.36.
CHIX:DMPd's PEG Ratio is ranked worse than 61.85% of 346
companies
in the Drug Manufacturers industry
Industry Median: 1.695
vs CHIX:DMPd: 2.57
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Dermapharm Holding SE (CHIX:DMPd) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DMPD vs ZTS, UTHR, VTRS: PEG Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Dermapharm Holding SE (CHIX:DMPD) has a PEG Ratio of 2.53 as of Jun. 30, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Dermapharm Holding SE and its competitors. This is 86% above median its historical median of 1.36. Over the past decade, Dermapharm Holding SE's PEG Ratio has ranged from 0.57 to 8.12. According to the industry distribution chart, Dermapharm Holding SE ranks #214 out of 346 companies in the Drug Manufacturers industry, placing it in the top 61.8%.
Is Dermapharm Holding SE's PEG Ratio too high?
Dermapharm Holding SE's current PEG Ratio of 2.53 is 86% above median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 8.12. The Drug Manufacturers industry median PEG Ratio is 1.70. Dermapharm Holding SE's value of 2.53 is 49.3% above this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #214 out of 346 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #214 out of 346 companies for PEG Ratio. This places Dermapharm Holding SE in the lower half of its industry. The industry median PEG Ratio is 1.70. Dermapharm Holding SE's value of 2.53 is 49.3% above this benchmark. Historically, Dermapharm Holding SE's own PEG Ratio has ranged from 0.57 to 8.12 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 1.70, Dermapharm Holding SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current PEG Ratio of 2.53 is 49.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current PEG Ratio is 2.53, which is 86% above median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current PEG Ratio of 2.53. The stock's GF Value™ is €38.59, compared to a current price of €46.18 — trading 19.7% above its estimated fair value. The current PEG Ratio is 2.53, which is 86% above median its 10-year median of 1.36 and 49.3% above the Drug Manufacturers industry median of 1.70. Dermapharm Holding SE's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current PEG Ratio is 2.53 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 19.7% above its estimated GF Value™ of €38.59.
Key valuation signals for CHIX:DMPD:
PEG Ratio: 2.53 (86% above median its 10-year median of 1.36)
GF Value™: €38.59 vs. price of €46.18 (19.7% above fair value)
Industry Position: 49.3% above the Drug Manufacturers median (#214 of 346)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
